Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Aquila_Biolabs_GmbH
|
| gptkbp:awards |
various industry awards
|
| gptkbp:businessModel |
biopharmaceutical development
|
| gptkbp:CEO |
gptkb:Peter_Heinrich
|
| gptkbp:clinicalTrials |
improved patient outcomes
ongoing clinical trials Phase 1/2 multiple cancer therapies T cell receptor therapies multiple therapeutic candidates in development published clinical results various clinical trial sites various phases of clinical trials |
| gptkbp:collaborations |
gptkb:University_of_Munich
academic institutions |
| gptkbp:communityEngagement |
patient advocacy groups
|
| gptkbp:communityOutreach |
international collaborations
|
| gptkbp:communityPartnerships |
collaborative research agreements
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financialPerformance |
positive financial growth
|
| gptkbp:financials |
annual financial reports
|
| gptkbp:focus |
immunotherapy
|
| gptkbp:founded |
1994
|
| gptkbp:hasPrograms |
composed of industry experts
|
| gptkbp:headquarters |
gptkb:Martinsried,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
MediGene AG
|
| gptkbp:impact |
personalized medicine
|
| gptkbp:innovation |
focus on innovative therapies
|
| gptkbp:investmentFocus |
R&D activities
institutional and private investors active investor communication strong investor backing |
| gptkbp:leadership |
experienced management team
|
| gptkbp:manufacturer |
active in the biotechnology sector
|
| gptkbp:market |
€200 million (2021)
European_and_US_markets |
| gptkbp:marketSegment |
targeted marketing strategies
|
| gptkbp:partnerships |
gptkb:Eisai_Co.,_Ltd.
biopharmaceutical companies |
| gptkbp:patentCitation |
numerous patents in immunotherapy
|
| gptkbp:products |
T cell therapies
ongoing product development efforts |
| gptkbp:regulatoryCompliance |
FDA_and_EMA_submissions
|
| gptkbp:research |
secured research funding
|
| gptkbp:research_areas |
oncology
focus on innovative therapies. |
| gptkbp:researchFocus |
cell-based therapies
dedicated to patient care |
| gptkbp:researchInterest |
joint research projects
numerous peer-reviewed articles |
| gptkbp:revenue |
€20 million (2020)
|
| gptkbp:stockSymbol |
MDG1
|
| gptkbp:strategicGoals |
expand product pipeline
|
| gptkbp:subsidiary |
gptkb:Medigene_Inc.
|
| gptkbp:sustainabilityInitiatives |
environmental responsibility programs
|
| gptkbp:technology |
T cell receptor technology
|
| gptkbp:tradedOn |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:tributaryOf |
various cancer indications
|
| gptkbp:website |
www.medigene.com
|